C
Changgui Li
Researcher at Chinese Center for Disease Control and Prevention
Publications - 20
Citations - 2788
Changgui Li is an academic researcher from Chinese Center for Disease Control and Prevention. The author has contributed to research in topics: Medicine & Vaccination. The author has an hindex of 7, co-authored 7 publications receiving 1671 citations.
Papers
More filters
Journal ArticleDOI
Development of an inactivated vaccine candidate for SARS-CoV-2.
Qiang Gao,Linlin Bao,Haiyan Mao,Lin Wang,Kangwei Xu,Minnan Yang,Li Yajing,Ling Zhu,Nan Wang,Zhe Lv,Hong Gao,Ge Xiaoqin,Biao Kan,Yaling Hu,Jiangning Liu,Fang Cai,Deyu Jiang,Yanhui Yin,Cheng-Feng Qin,Jing Li,Xuejie Gong,Xiuyu Lou,Wen Shi,Dongdong Wu,Hengming Zhang,Zhu Lang,Wei Deng,Li Yurong,Jinxing Lu,Changgui Li,Xiangxi Wang,Weidong Yin,Yanjun Zhang,Chuan Qin +33 more
TL;DR: Preclinical results of an early vaccine candidate called PiCoVacc, which protected rhesus macaque monkeys against SARS-CoV-2 infection when analyzed in short-term studies, support the clinical development and testing of Pi coVacc for use in humans.
Journal ArticleDOI
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Yanjun Zhang,Gang Zeng,Hongxing Pan,Changgui Li,Yaling Hu,Kai Chu,Weixiao Han,Zhen Chen,Rong Tang,Weidong Yin,Xin Chen,Yuansheng Hu,Xiao-Yong Liu,Cong-Bing Jiang,Jingxin Li,Minnan Yang,Yan Song,Xiangxi Wang,Qiang Gao,Fengcai Zhu +19 more
TL;DR: The primary safety endpoint was adverse reactions within 28 days after injection in all participants who were given at least one dose of study drug (safety population).
Journal ArticleDOI
Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial
Jiang-Tao Lin,Jiansan Zhang,Xiao-Ping Dong,Han-Hua Fang,Jiang-Ting Chen,Nan Su,Qiang Gao,Zhenshan Zhang,Yuxuan Liu,Zhihong Wang,Meng Yang,Rui-Hua Sun,Changgui Li,Su Lin,Mei Ji,Yan Liu,Xu Wang,John Wood,Zijian Feng,Yu Wang,Weidong Yin +20 more
TL;DR: A two-dose regimen of an adjuvanted 10 microg inactivated whole-virion H5N1 vaccine met all European regulatory requirements for annual licensing of seasonal influenza vaccine.
Posted ContentDOI
Rapid development of an inactivated vaccine for SARS-CoV-2
Qiang Gao,Linlin Bao,Haiyan Mao,Lin Wang,Kangwei Xu,Minnan Yang,Li Yajing,Ling Zhu,Nan Wang,Zhe Lv,Hong Gao,Ge Xiaoqin,Biao Kan,Yaling Hu,Jiangning Liu,Fang Cai,Deyu Jiang,Yanhui Yin,Cheng-Feng Qin,Jing Li,Xuejie Gong,Xiuyu Lou,Wen Shi,Dongdong Wu,Hengming Zhang,Zhu Lang,Wei Deng,Li Yurong,Jinxing Lu,Changgui Li,Xiangxi Wang,Weidong Yin,Yanjun Zhang,Chuan Qin +33 more
TL;DR: Systematic evaluation of PiCoVacc via monitoring clinical signs, hematological and biochemical index, and histophathological analysis in macaques suggests that it is safe, and data support the rapid clinical development of SARS-CoV-2 vaccines for humans.
Posted ContentDOI
Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial
Yanjun Zhang,Gang Zeng,Hongxing Pan,Changgui Li,Biao Kan,Yaling Hu,Haiyan Mao,Qian-Qian Xin,Kai Chu,Weixiao Han,Zhen Chen,Rong Tang,Weidong Yin,Xin Chen,Xuejie Gong,Chuan Qin,Yuansheng Hu,Xiao-Yong Liu,Guo-Liang Cui,Cong-Bing Jiang,Hengming Zhang,Jingxin Li,Minnan Yang,Xiao-Juan Lian,Yan Song,Jinxing Lu,Xiangxi Wang,Miao Xu,Qiang Gao,Fengcai Zhu +29 more
TL;DR: Favorable safety and immunogenicity of CoronaVac was demonstrated on both schedules and both dosages, which support the conduction of phase 3 trial with optimum schedule/dosage per different scenarios.